Research
Energy balance
Semaglutide is projected to increase annual health care spending by $23 billion.
Healthcare systems should prepare for increased spending associated with the adoption of semaglutide.
StrongSupportsmedium confidence
Treatment with semaglutide was projected to increase annual health care spending by $23 billion.
Why this rating
Based on a population-based cohort simulation study design.
Source
Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adults
Susan Hennessy et al. · JAMA Cardiology · 2026
DOI 10.1001/jamacardio.2025.5243
cohort · n=4000000Cited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Adding semaglutide to usual care in US adults without diabetes is projected to avert 358,400 major adverse cardiovascular events (MACE) at a cost of $148,100 per quality-adjusted life-year (QALY) gained.Strong
- Semaglutide would be cost-effective at a threshold of $120,000 per QALY gained if the annual cost were lowered by 18% to $7,055.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →